European Psychiatry
March 1, 2023
V. W. L. Tsang, R. Moyer, P. Kryskow et al.
2 citations
IntroductionHealthcare practitioners (HCPs) are facing a mental health crisis. Group therapies have long been used to treat symptoms associated with PTSD, anxiety and/or depression, however no studies have investigated the role of implementing group therapy with and without ketamine-assisted therapies (KaT).ObjectivesThe current study investigated the effects of the Roots to Thrive (RTT) group...
European Psychiatry
March 1, 2023
K. P. Kuypers
2 citations
Abstract Decades ago, the classical psychedelics psilocybin and LSD entered the therapeutic setting and already then showed their therapeutic potential in the treatment of psychiatric disorders. For thousands of years another psychedelic, ayahuasca, is being used by tribes in western Amazonia for healing and divination, and in recent years its use has expanded worldwide. Research into the...
European Psychiatry
March 1, 2023
E. Prades, A. Torres, P. Díez et al.
1 citation
Introduction Ayahuasca is a traditional brew containing the psychedelic 5-DMT (a tryptamine that acts as a 5HT2A-R agonist) used to achieve non-ordinary states of consciousness, with a long tradition among various cultures in ritual and therapeutic contexts. Ayahuasca is being studied as potential treatment in Mental Health, which has led to non-controlled and recreational use. This has led to...
European Psychiatry
March 1, 2023
Guy M. Goodwin, Lindsey Marwood, Sunil Mistry et al.
1 citation
Introduction COMP360 is a synthetic, proprietary, purified form of psilocybin in development for treatment-resistant depression (TRD) with FDA Breakthrough Therapy designation. In a recent phase IIb study, COMP360 psilocybin 25mg was superior to 1mg on change from baseline (CFB) to Week 3 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score (primary efficacy endpoint), when...
European Psychiatry
March 1, 2023
V. W. L. Tsang, Brendan Tao, Shannon Dames et al.
1 citation
IntroductionKetamine has been increasingly used to treat mental health conditions yet there is a lack of safety data on intramuscular (IM) and sublingual (SL) dosing in a community setting. The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a 12-week program with 12 Community of Practice (CoP) group therapy sessions and three ketamine sessions.ObjectivesTo provide preliminary...
European Psychiatry
March 1, 2023
René Zeiss
Introduction Psilocybin is considered a classical psychedelic and is increasingly attracting scientific and media attention as an alternative approach to the treatment of various mental disorders. Apart from its efficacy, an important question is the tolerability and safety of psilocybin in general and in a controlled environment. Accurate knowledge of drug safety aspects might be essential for...
European Psychiatry
March 1, 2023
J. H. Shepherd, Caitlin Baten, A. C. Klassen et al.
Introduction Curiosity toward the effects of psychedelic drugs on neural activation has increased due to their potential therapeutic benefits, particularly serotonergic psychedelics that act as 5-HT2A receptor agonists such as LSD, psilocybin, and MDMA. However, the pattern of their effects on neural activity in various brain regions in both clinical and healthy populations is still not well...
European Psychiatry
March 1, 2023
Rachel Cohen, Itamar Pereira, M. Marguilho et al.
Introduction Sleep disorders (e.g., insomnia) are extremely prevalent in our population and are intimately associated with distress and productivity impairment. It is estimated that between 40 to 60% of people suffering from a sleep disorder have an underlying psychiatric diagnosis. Mindfulness, which is described as the quality or state of being self-conscious or aware of something, has shown...
European Psychiatry
March 1, 2023
R. Sousa, Luís Costa, J. Brás et al.
Introduction Substance use disorders(SUDs) are a major health concern and current treatment interventions have proven only limited success. Despite increasing effectiveness, still about 50–60% relapse within 6–12 months after treatment [Cornelius et al ., Addict Behav. 2003;28 381-386]. SUDs are defined as chronic disorders of brain reward system, motivation, and memory processes that have gone...
European Psychiatry
March 1, 2023
J. Ramírez González, I. Fernández Márquez, Serafín González et al.
Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potential of hallucinogens were blocked due to their misuse in the young population. At present, psilocybin is re-emerging as the center of attention due to its possible therapeutic potential in different psychiatric pathologies such as depression, anxiety...
European Psychiatry
March 1, 2023
S. Kamrun, T. Sultana, F. Faruki et al.
Introduction There has been an increase in the use of new psychoactive substances containing synthetic cannabinoids in recent years. It is also known as K2, spice, or fake weed, and these are popular as recreational drugs [Kourouni I et al. JAMA NetW Open 2020 Jul; 1;3(7): e208516]. CB1 agonists in SCs mimic the effects of cannabis, making users feel happy and relaxed. However, recreational SCs...
European Psychiatry
March 1, 2023
Pierre A Geoffroy, Rodolphe Borand, Marine Ambar Akkaoui et al.
Introduction Sleep and circadian markers are of increasingly growing interest to help better predicting suicide. Indeed, specific sleep disorders and circadian rhythm disorders have been associated to suicidal behaviors, and the most replicated findings are insomnia and nightmares. Nevertheless, these interesting preliminary studies did not examine the chronology and trajectories of these dream...
European Psychiatry
March 1, 2023
Erhan Kavakbasi, Bernhard T Baune
IntroductionNMDA-Receptor antagonists have rapid antidepressant and antisuicidal properties. However, the antidepressant effect is short lasting raising the question of best maintenance strategy, which is unanswered so far. Invasive vagus nerve stimulation (VNS) as a treatment option for refractory and chronic major depression was shown to reduce the need of maintenance treatment sessions in...
European Psychiatry
March 1, 2023
B. Roméo, V. Lestra, Catherine Martelli et al.
Introduction The vulnerability-stress-inflammation model is a well-known psychopathological model in patients with psychosis. It implies an imbalance of the microglia activation (M1/M2 pathways’ homeostasis) leading to an over-expression of pro-inflammatory cytokines. However, despite a higher prevalence of cannabis (THC) consumption in patients with psychosis, few studies have investigated the...
European Psychiatry
March 1, 2023
C. Loureiro, Fabiana Corsi-Zuelli, Helene A Fachim et al.
Introduction Gene-environment interactions increase psychosis risk (Gayer-Anderson et al. Soc Psychiatry Psychiatr Epidemiol 2020; 55(5):645-657). However, identifying the genetic variants involved and how they interact with environmental risk factors underlying psychosis remains challenging. Objectives To investigate whether there are gene-environment interactions in the relationships of...
European Psychiatry
March 1, 2023
Ali Kandeğer, Şerife Odabaş Ünal, M. T. Ergün
Introduction: Excessive mind wandering is a common feature of ADHD in adulthood also referred to as mental restlessness and ceaseless mental overactivity. ADHD is a predisposing factor for many psychiatric symptoms, especially negative emotions such as depression and anxiety. Rumination is thought to be a mediator for depression in individuals with ADHD. The above-mentioned mental processes may...
European Psychiatry
March 1, 2023
M. Kacem, W. Bouali, M. Henia et al.
Introduction Cannabis is the most widely used illicit drug; 3.8% of the world’s population consumes cannabis on a regular basis. Cannabis use–associated alterations in the domain of cognition have been extensively studied. Objectives To research memory deficiency in the young consumers of cannabis in Tunisia. Methods This is a transversal descriptive study conducted during two months (January...
European Psychiatry
March 1, 2023
M. C. Q. Lin, H. Lee, V.-W.-L. Tsang et al.
Introduction Despite emerging evidence suggesting the efficacy of psilocybin in the treatment of mood disorders such as depression, the exact mechanisms by which psilocybin is able to elicit these antidepressant effects remains unknown. Objectives As the use of psilocybin as a treatment modality for depression has garnered increasing interest, this study aims to summarize the existing evidence...
European Psychiatry
March 1, 2023
E. Bergaoui, R. Lansari, O. Chehaider et al.
IntroductionCannabis use is frequent among patients with psychotic disorders. However, the relationship between cannabis consumption and transition to psychosis has not been fully elucidated.ObjectivesThe aim of this study was to assess the prevalence of cannabis use in first episode psychosis and its correlation with transistion to psychosis and severity of symptoms.MethodsA cross-sectional...
European Psychiatry
March 1, 2023
A. T. Guterman, K. Feffer, A. Z. Gershi
IntroductionDepressive disorders are among the leading causes of disability. The lifetime risk for developing clinically significant depression is estimated around 15%. Multiple studies have found female-male ratio of 2:1 across nations and cultures. The reason for this marked difference is still not clear, although several theories addressing social, biological, and environmental contributors...
European Psychiatry
June 1, 2022
Pierre Chue, A. Andreiev, E. Bucuci et al.
6 citations
Introduction The 5-HT 2A agonist classic psychedelic, psilocybin (O-phosphoryl-4-hydroxy-N,N-dimethyltryptamine) is a tryptophan, indole-based alkaloid present in up to 2% of certain hallucinogenic “magic” mushroom species; typically Psilocybe azurescens, semilanceata, and cyanescens,. In addition, mushrooms may contain psilocin (4-hydroxy-N,N-dimethyltryptamine). Both are indolylalkylamines...
European Psychiatry
June 1, 2022
Kaushal Shah, C. Trivedi, D. Kamrai et al.
6 citations
Introduction Psilocybin is a psychedelic drug found in mushrooms, often referred to as magic mushrooms due to its visual and auditory hallucinations effects upon ingestion. It is a Schedule I drug per DEA, and the FDA has not approved psilocybin for medicinal purposes. However, recent studies have shown promising therapeutic use to treat depression. Objectives To identify current use,...
European Psychiatry
June 1, 2022
Johannes T. Reckweg, Natasha L. Mason, Cees van Leeuwen et al.
3 citations
Introduction 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) is a tryptamine with ultra-rapid onset and short duration of psychedelic effects. Prospective studies for other tryptamines have suggested beneficial effects on mental health outcomes. Objectives In preparation for a study in patients with depression, the present study GH001-HV-101 aimed to assess the impact of four different dose levels...
European Psychiatry
June 1, 2022
G. Simões, S. Jesús, R. Silva
1 citation
Introduction Ayahuasca (AYA) is a psychotropic plant from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that AYA may have therapeutic potential in the treatment of mental health disorders like depression – a common life-disrupting, highly recurrent disorder – that is among the leading causes of disability worldwide. Objectives The...
European Psychiatry
June 1, 2022
M. Turki, O. Abidi, S. Ellouze et al.
1 citation
Introduction Ketamine is routinely used for anesthetic induction because of its dissociative properties. Recently, it has attracted attention as a rapid-acting anti-depressant, but other studies have also reported its efficacy in the management of diverse psychiatric pathologies previously resistant to treatment. Objectives We aimed to review the efficacity of ketamine in the management of...